Physician profile
Francis Arena
NPI 1699760132
$1,004,735.77
in general payments reported to CMS, 2019-2025
53 companies · $62K in 2025
The $62K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193K · 2020: $80K · 2021: $96K · 2022: $182K · 2023: $266K · 2024: $126K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $367K · Travel and Lodging: $56K · Food and Beverage: $15K · Consulting Fee: $10K · Honoraria: $3,425 · Long Term Medical Supply Or Device Loan: $1,714 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $367,421.75 |
| Travel and Lodging | $56,198.99 |
| Food and Beverage | $14,786.91 |
| Consulting Fee | $10,346.50 |
| Honoraria | $3,425.00 |
| Long Term Medical Supply Or Device Loan | $1,714.23 |
| Education | $277.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $151,755.65 | 2019-2025 | Nerlynx |
| Daiichi Sankyo INC. | $130,642.27 | 2019-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals Lp | $100,599.36 | 2019-2025 | Enhertu |
| Incyte Corporation | $87,219.25 | 2021-2025 | Monjuvi, Monjuvi |
| Amgen INC. | $74,265.27 | 2019-2023 | Lumakras |
| Regeneron Healthcare Solutions, INC. | $65,328.47 | 2021-2024 | Libtayo |
| Gilead Sciences, INC. | $51,118.23 | 2021-2024 | Trodelvy |
| Celgene Corporation | $48,320.79 | 2019-2025 | Reblozyl |
| Stemline Therapeutics INC. | $47,444.26 | 2023-2024 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $40,583.88 | 2019-2025 | Reblozyl |
| Pfizer INC. | $38,962.94 | 2021-2024 | |
| Genzyme Corporation | $37,832.13 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $36,531.74 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Genentech USA, INC. | $16,482.56 | 2019-2023 | Venclexta |
| Array Biopharma INC | $16,406.94 | 2021-2024 | Braftovi, Lorbrena, Xalkori |
Show all 50 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Arena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.